FLT3-specific chimeric antigen receptors and methods using same
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsChristopher D. Chien, Terry J. Fry
Life of this patent
Estimating the term…
Abstract
An embodiment of the invention provides a chimeric antigen receptor (C AR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
Claims20
A chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain, wherein the antigen binding domain comprises a single chain variable fragment (scFv) comprising from N-terminus to C-terminus (a) the heavy chain variable region CDR1, CDR2, and CDR3 sequences of SEQ ID NOS:
- 6, 8, and 10 and (b) the light chain variable region CDR1, CDR2, and CDR3 sequences of SEQ ID NOS:
- 14, 16, and 18.
Dependencies are inferred from the claim text.